AstraZeneca PLC (AZN.L)
| Previous close | 7,632.00 |
| Open | 7,679.00 |
| Bid | 7,782.00 x 0 |
| Ask | 7,783.00 x 0 |
| Day's range | 7,642.00 - 7,808.70 |
| 52-week range | 6,736.00 - 10,120.00 |
| Volume | 2,049,853 |
| Avg. volume | 3,055,780 |
| Market cap | 102.21B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 35.72 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.07 (2.71%) |
| Ex-dividend date | 25 Feb 2021 |
| 1y target est | N/A |
- Business Wire
New Tezepelumab Data Continue to Strengthen Profile for a Broad Population of Severe Asthma Patients
Detailed results from the pivotal NAVIGATOR Phase III trial showed AstraZeneca and Amgen’s tezepelumab, a potential first-in-class treatment, demonstrated superiority across every primary and key secondary endpoint in a broad population of severe asthma patients, compared to placebo when added to standard of care (SoC).
- Business Wire
IMFINZI and tremelimumab With Chemotherapy Demonstrated Overall Survival Benefit in POSEIDON Trial for 1st-line Stage IV Non-small Cell Lung Cancer
POSEIDON was a Phase III trial of AstraZeneca’s IMFINZI® (durvalumab) plus platinum-based chemotherapy or IMFINZI, tremelimumab and chemotherapy versus chemotherapy alone in the 1st-line treatment of patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC).
- Business Wire
FARXIGA Approved in the US for the Treatment of Chronic Kidney Disease in Patients at Risk of Progression With and Without Type 2 Diabetes
AstraZeneca’s FARXIGA® (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the US to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death and hospitalization for heart failure (hHF) in adults with chronic kidney disease (CKD) at risk of progression.
